TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31519364

Group type: EXPERIMENTAL
Intervention: Video‐assisted thoracoscopic surgery (VATS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intrapleural fibrinolytic therapy (IFT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: VATS
Number of subjects: 41

Group type: COMPARATOR
Intervention: IFT
Number of subjects: 41
Study: 30806130

Group type: EXPERIMENTAL
Intervention: Mixed pure tones sound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Broad band noise (BBN) sound therapy
Number of subjects: 0
Study: 28831695

Group type: EXPERIMENTAL
Intervention: Simplest model for insulin pharmacokinetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Models with increasing complexity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Most complex models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best model with two linear subcutaneous compartments
Number of subjects: 0
Study: 26425555

Group type: EXPERIMENTAL
Intervention: TCA haplotype (rs12483428-rs987195-rs4817027)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: CC haplotype (rs969885-rs987195)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: AA genotype at rs4817027
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: CG haplotype (rs987195-rs969885)
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Copy number variants of the MIR155HG/miR-155 gene
Number of subjects: 538
Study: 23657930

Group type: EXPERIMENTAL
Intervention: Ginger powder
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 100
Study: 19681940

Group type: EXPERIMENTAL
Intervention: Immediate loading of two bar‐splinted SLActive implants with an implant‐retained mandibular overdenture
Number of subjects: 124
Study: 19301135

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention delivered at training sites in collaboration with unions.
Number of subjects: 1213
Study: 17534806

Group type: EXPERIMENTAL
Intervention: One drop of cyclopentolate 1%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Two drops of cyclopentolate 1%
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Three drops of cyclopentolate 1%
Number of subjects: 96
Study: 14745567

Group type: EXPERIMENTAL
Intervention: Shed blood collection and reinfusion using SureTrans System (Group A, n=194)
Number of subjects: 365

Group type: COMPARATOR
Intervention: No shed blood collection and reinfusion (Control Group B, n=171)
Number of subjects: 365
Study: 11443604

Group type: EXPERIMENTAL
Intervention: 18 grays (Gy) of cranial radiation therapy
Number of subjects: 201
Study: 9856729

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 2408
Study: 8576295

Group type: EXPERIMENTAL
Intervention: mebeverine plain 135 mg, two capsules t.i.d.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mebeverine sustained release 200 mg (SR), two capsules b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both formulations (mebeverine plain and mebeverine SR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mebeverine plain
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: mebeverine SR
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 60
Study: 2142109

Group type: EXPERIMENTAL
Intervention: Danazol (600 mg a day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA; 100 mg a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 357069

Group type: EXPERIMENTAL
Intervention: 200 mg fenmetozole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of 200 mg fenmetozole and 50 ml/70 kg ethanol
Number of subjects: 8

Group type: COMPARATOR
Intervention: None (control for fenmetozole)
Number of subjects: 8

Group type: COMPARATOR
Intervention: None (control for ethanol)
Number of subjects: 8
Study: 31136652

Group type: EXPERIMENTAL
Intervention: Training group (trigram character-recognition trials over 4 consecutive days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 26
Study: 27177885

Group type: EXPERIMENTAL
Intervention: Unadjusted cluster-level analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline covariate adjusted cluster-level analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear mixed model analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster mean imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0
Study: 25740700

Group type: EXPERIMENTAL
Intervention: Tube current limitation at 210 mA
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tube current limitation at 450 mA
Number of subjects: 118

Group type: COMPARATOR
Intervention: No limitation
Number of subjects: 118
Study: 23084438

Group type: EXPERIMENTAL
Intervention: Telephone lactation counselling (n=179)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Current conventional care of postnatal breastfeeding support (Control group, n=178)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (n=178)
Number of subjects: 357
Study: 20970833

Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Trospium XR
Number of subjects: 176
Study: 19752581

Group type: EXPERIMENTAL
Intervention: 600 mg/day of ARA-enriched triglyceride (SUNTGA40S; containing 240 mg ARA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Olive oil capsules (inactive placebo)
Number of subjects: 25
Study: 16648511

Group type: EXPERIMENTAL
Intervention: Prophylactic trolamine emulsion
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Interventional trolamine emulsion
Number of subjects: 547

Group type: COMPARATOR
Intervention: Institutional preference
Number of subjects: 547
Study: 12924804

Group type: EXPERIMENTAL
Intervention: Neomune
Number of subjects: 36
Study: 10570589

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 40
Study: 8891660

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (pre-L-dopa administration)
Number of subjects: 11
Study: 1676392

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol with nizatidine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 12
Study: 6837464

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sodium meglumine diatrizoate (Renografin‐76)
Number of subjects: 50
Study: 4027125

Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) administered 1 h after mefenamic acid
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) and hyoscine butylbromide (20 mg) administered after mefenamic acid
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hyoscine butylbromide (20 mg) administered immediately after mefenamic acid
Number of subjects: 9
Study: 28834955

Group type: EXPERIMENTAL
Intervention: Triple ART
Number of subjects: 289

Group type: COMPARATOR
Intervention: Short course ZDV
Number of subjects: 289
Study: 27859666

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) for 12 weeks
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATM) for 12 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Methylphenidate (MPH) and Atomoxetine (ATM)
Number of subjects: 86
Study: 25159085

Group type: EXPERIMENTAL
Intervention: Bright light therapy (5,000 lx)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo control (230 lx)
Number of subjects: 125
Study: 22729470

Group type: EXPERIMENTAL
Intervention: Structum (500 mg twice daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 20507203

Group type: EXPERIMENTAL
Intervention: Tailored Internet
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tailored Print
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard Internet
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 38
Study: 18451114

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv during induction of anesthesia
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv approximately 30 min before the end of surgery
Number of subjects: 94

Group type: COMPARATOR
Intervention: Haloperidol 2 mg iv (both groups)
Number of subjects: 94
Study: 16416368

Group type: EXPERIMENTAL
Intervention: Fat-enriched artificial liquid diet (20 nonprotein kcal/kg per day) plus normal meals (group B, n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional diet supplying 35 nonprotein kcal and 1.1 g of protein/kg per day (group A, n = 11)
Number of subjects: 23
Study: 14569405

Group type: EXPERIMENTAL
Intervention: LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat alpha‐linolenic acid metabolites)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Formula devoid of LCP
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LCP supplemented formula
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: LCP supplemented formula and formula devoid of LCP
Number of subjects: 29
Study: 10453581

Group type: EXPERIMENTAL
Intervention: Yu Cong Tang (TCM decoction)
Number of subjects: 0
Study: 8917256

Group type: EXPERIMENTAL
Intervention: Stenting after PTCA
Number of subjects: 119

Group type: COMPARATOR
Intervention: PTCA only (Control)
Number of subjects: 119
Study: 1886483

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 6352884

Group type: EXPERIMENTAL
Intervention: Insulin injection 30 to 60 minutes before breakfast
Number of subjects: 23

Group type: COMPARATOR
Intervention: Insulin injection 5 minutes prior to breakfast
Number of subjects: 23
Study: 31665074

Group type: EXPERIMENTAL
Intervention: EASE intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29851415

Group type: EXPERIMENTAL
Intervention: Circulating β cell‐reactive CD8+ T cell subsets (specifically CD57+ effector memory CD8+ T cells)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Autoreactive CD57+ effector memory CD8+ T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Network association modeling of β cell‐reactive CD57+ effector memory CD8+ T cell subsets
Number of subjects: 0
Study: 27271658

Group type: EXPERIMENTAL
Intervention: High-concentration glucose solution (250 mL containing 50% glucose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral supplementation plus high-concentration glucose solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8.5% amino acids solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (oral supplementation only)
Number of subjects: 0
Study: 24297972

Group type: EXPERIMENTAL
Intervention: Community-based multilevel intervention
Number of subjects: 2016

Group type: COMPARATOR
Intervention: Comparison area
Number of subjects: 2016
Study: 22782542

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (Neutral and Positive anticipation)
Number of subjects: 0
Study: 18987358

Group type: EXPERIMENTAL
Intervention: lenalidomide 10 mg/day
Number of subjects: 47
Study: 17693914

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation plus medicated bronchoalveolar lavage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume-controlled ventilation and bronchosuction
Number of subjects: 20
Study: 16163098

Group type: EXPERIMENTAL
Intervention: Infiltration solutions at body temperature (37 degrees C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Infiltration solutions at room temperature (24 degrees C)
Number of subjects: 30
Study: 12412978

Group type: EXPERIMENTAL
Intervention: 100 microg salmeterol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol
Number of subjects: 20
Study: 10472853

Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.1 mg
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.25 mg
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.5 mg
Number of subjects: 1176

Group type: COMPARATOR
Intervention: E2 1 mg (unopposed)
Number of subjects: 1176
Study: 9087885

Group type: EXPERIMENTAL
Intervention: Treatment suggested by the trained ART (N = 21)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Consensus of two senior psychiatrists (N = 33)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Treatment suggested by ART
Number of subjects: 211
Study: 1846790

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (50 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sodium bicarbonate (1.5 mmol/kg body weight)
Number of subjects: 10
Study: 6824557

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31862249

Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.7 mg/kg per day
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.2 mg/kg per day
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 29921734

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa-epbx
Number of subjects: 612

Group type: COMPARATOR
Intervention: Intravenous epoetin alfa
Number of subjects: 612
Study: 27438078

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 24925713

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched fish oil (600 mg daily)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 22250633

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (weekly for 10 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.1% tretinoin ointment (topically for 10 weeks)
Number of subjects: 60
Study: 20381161

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 18559351

Group type: EXPERIMENTAL
Intervention: LMA-Supreme (SLMA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: LMA-Proseal (PLMA)
Number of subjects: 36
Study: 15921786

Group type: EXPERIMENTAL
Intervention: 5-min test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10-min test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15-min test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All ramp rates
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall protocol effect
Number of subjects: 90
Study: 11794427

Group type: EXPERIMENTAL
Intervention: Step-down therapy with pravastatin (dosing frequency changed from daily to every other day)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Step-down therapy with pravastatin (daily dose halved)
Number of subjects: 104
Study: 10463515

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 200/100 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400/200 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 800/400 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 7615103

Group type: EXPERIMENTAL
Intervention: Dopamine (DA) infusion (0.4 micrograms/kg per minute)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 16
Study: 1696309

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) - two cycles of cisplatin, vindesine, and bleomycin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Radiation therapy (RT) - 55 Gy
Number of subjects: 96
Study: 870782

Group type: EXPERIMENTAL
Intervention: 15-min duration jogging program, 3 days/week
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 3 days/week
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 45-min duration jogging program, 3 days/week
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 1 day/week
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 30-min duration jogging program, 5 days/week
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 31262065

Group type: EXPERIMENTAL
Intervention: Eating competent parents (EC)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Strivers (n = 151)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Thrivers (n = 255)
Number of subjects: 424
Study: 28597697

Group type: EXPERIMENTAL
Intervention: Unassisted cough
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Manually assisted cough
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mechanically assisted cough
Number of subjects: 48
Study: 26618915

Group type: EXPERIMENTAL
Intervention: Community-based rehabilitation (CBR) intervention
Number of subjects: 0
Study: 23143034

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory task with memory load
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Verbal working memory task with memory load
Number of subjects: 304

Group type: COMPARATOR
Intervention: Visuospatial working memory task without memory load
Number of subjects: 304

Group type: COMPARATOR
Intervention: Verbal working memory task without memory load
Number of subjects: 304
Study: 21623611

Group type: EXPERIMENTAL
Intervention: Charcoal filter
Number of subjects: 30
Study: 18524792

Group type: EXPERIMENTAL
Intervention: Adalimumab treatment for 24 weeks
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Enthesitis score
Number of subjects: 245

Group type: COMPARATOR
Intervention: Enthesitis presence
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Interobserver ICC
Number of subjects: 245
Study: 16326406

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) with Adriamycin (20 mg/m2), vincristine (1.5 mg/m2), and cisplatin (40 mg/m2) dispersed in 5-10 mL lipiodol, performed 1-3 times.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) with Adriamycin, vincristine, and cisplatin.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) followed by surgery.
Number of subjects: 8
Study: 15235875

Group type: EXPERIMENTAL
Intervention: Iron reduction therapy by biweekly phlebotomy for 3 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group with regular blood tests for 3 months
Number of subjects: 33
Study: 11263780

Group type: EXPERIMENTAL
Intervention: High-dose penicillamine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Improvement in HAQ DI score over 2 years
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baseline HAQ DI score and total skin score
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Changes in HAQ DI score and total skin score over 2 years
Number of subjects: 134
Study: 10920881

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (matelin and immune RNA)
Number of subjects: 51
Study: 8138886

Group type: EXPERIMENTAL
Intervention: Malingering condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Modified responses
Number of subjects: 60
Study: 3340658

Group type: EXPERIMENTAL
Intervention: Heavy-resistance training for triceps surae muscles, 24 sessions over 8 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 28
Study: 31442783

Group type: EXPERIMENTAL
Intervention: Web-based psychoeducation
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Home-based psychoeducation
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study: 28941216

Group type: EXPERIMENTAL
Intervention: ABT-122 1 mg/kg every other week (4 doses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ABT-122 0.5, 1.5, or 3 mg/kg weekly (8 doses)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ABT-122 (all doses)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27148986

Group type: EXPERIMENTAL
Intervention: Metal-Ceramic Fixed Dental Prostheses (MC-FDPs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All-Ceramic Fixed Dental Prostheses (AC-FDPs)
Number of subjects: 34
Study: 23286311

Group type: EXPERIMENTAL
Intervention: 20 mg of memantine daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21056046

Group type: EXPERIMENTAL
Intervention: BDNF Val66Met polymorphism (Val/Met-Met/Met genotype)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Val/Val genotype
Number of subjects: 211
Study: 19154996

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg daily from 20 weeks of pregnancy until delivery)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo (daily from 20 weeks of pregnancy until delivery)
Number of subjects: 235
Study: 17094031

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Wait-list condition (WLC)
Number of subjects: 68
Study: 15358694

Group type: EXPERIMENTAL
Intervention: Bronchoscopy with endobronchial biopsy (EBB) and bronchoalveolar lavage (BAL)
Number of subjects: 159
Study: 11704369

Group type: EXPERIMENTAL
Intervention: heparin-coated beStent
Number of subjects: 145

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 145
Study: 9150830

Group type: EXPERIMENTAL
Intervention: Middle plasma level range
Number of subjects: 95

Group type: COMPARATOR
Intervention: Low plasma level range
Number of subjects: 95

Group type: COMPARATOR
Intervention: High plasma level range
Number of subjects: 95
Study: 7893584

Group type: EXPERIMENTAL
Intervention: Isoprenaline (0.25-8 micrograms) and Metoprolol (0.5-8 mg) administered intravenously
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 25
Study: 3148787

Group type: EXPERIMENTAL
Intervention: Insulin alone (group A; n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 3.5 mg b.i.d. glibenclamide plus small amounts of intermediate insulin (group B; n = 8)
Number of subjects: 16